Goodman Advisory Group LLC Trims Stock Position in DexCom, Inc. $DXCM

Goodman Advisory Group LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 61.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,544 shares of the medical device company’s stock after selling 11,944 shares during the period. Goodman Advisory Group LLC’s holdings in DexCom were worth $474,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DXCM. Louisiana State Employees Retirement System purchased a new position in shares of DexCom during the 1st quarter worth approximately $2,820,000. Fifth Third Wealth Advisors LLC lifted its stake in DexCom by 7.4% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 5,694 shares of the medical device company’s stock valued at $358,000 after buying an additional 394 shares in the last quarter. OP Asset Management Ltd purchased a new stake in DexCom in the 1st quarter valued at approximately $2,541,000. Banque Cantonale Vaudoise grew its holdings in DexCom by 338.2% during the 1st quarter. Banque Cantonale Vaudoise now owns 30,080 shares of the medical device company’s stock valued at $1,888,000 after buying an additional 23,216 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in DexCom by 40.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,719,249 shares of the medical device company’s stock valued at $107,969,000 after buying an additional 492,800 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,694 shares of company stock valued at $3,343,977 in the last three months. Company insiders own 0.28% of the company’s stock.

DexCom Trading Up 2.2%

Shares of DXCM opened at $70.14 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a market capitalization of $27.06 billion, a PE ratio of 29.97, a price-to-earnings-growth ratio of 1.16 and a beta of 1.45. The stock has a fifty day moving average of $67.65 and a two-hundred day moving average of $68.08. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Stifel Nicolaus set a $90.00 price target on DexCom and gave the stock a “buy” rating in a report on Friday, June 5th. Bank of America decreased their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Benchmark restated a “buy” rating on shares of DexCom in a report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating and set a $95.00 price target (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $84.88.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.